168 related articles for article (PubMed ID: 16624725)
1. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.
Impellizeri JA; Howell K; McKeever KP; Crow SE
Vet J; 2006 May; 171(3):556-8. PubMed ID: 16624725
[TBL] [Abstract][Full Text] [Related]
2. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma.
Rue SM; Eckelman BP; Efe JA; Bloink K; Deveraux QL; Lowery D; Nasoff M
Vet Immunol Immunopathol; 2015 Apr; 164(3-4):148-59. PubMed ID: 25764941
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
4. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
[TBL] [Abstract][Full Text] [Related]
5. [Rituximab in the treatment of B-cell non-Hodgkin lymphoma].
Mitrović Z; Aurer I
Lijec Vjesn; 2006; 128(1-2):36-42. PubMed ID: 16640226
[TBL] [Abstract][Full Text] [Related]
6. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
7. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
[TBL] [Abstract][Full Text] [Related]
8. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
Zhou X; Hu W; Qin X
Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
[TBL] [Abstract][Full Text] [Related]
9. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
11. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma.
Jubala CM; Wojcieszyn JW; Valli VE; Getzy DM; Fosmire SP; Coffey D; Bellgrau D; Modiano JF
Vet Pathol; 2005 Jul; 42(4):468-76. PubMed ID: 16006606
[TBL] [Abstract][Full Text] [Related]
12. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
Takei K; Yamazaki T; Sawada U; Ishizuka H; Aizawa S
Leuk Res; 2006 May; 30(5):625-31. PubMed ID: 16289746
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
[TBL] [Abstract][Full Text] [Related]
14. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
[TBL] [Abstract][Full Text] [Related]
15. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial.
Witzens-Harig M; Reiz M; Heiss C; Benner A; Hensel M; Neben K; Dreger P; Kraemer A; Ho AD
Ann Hematol; 2009 Jan; 88(1):51-7. PubMed ID: 18665360
[TBL] [Abstract][Full Text] [Related]
16. Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry.
Gelain ME; Mazzilli M; Riondato F; Marconato L; Comazzi S
Vet Immunol Immunopathol; 2008 Feb; 121(3-4):179-88. PubMed ID: 17981339
[TBL] [Abstract][Full Text] [Related]
17. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
18. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
[TBL] [Abstract][Full Text] [Related]
20. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Terui Y; Mishima Y; Sugimura N; Kojima K; Sakurai T; Mishima Y; Kuniyoshi R; Taniyama A; Yokoyama M; Sakajiri S; Takeuchi K; Watanabe C; Takahashi S; Ito Y; Hatake K
Clin Cancer Res; 2009 Apr; 15(7):2523-30. PubMed ID: 19276251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]